Abstract 55 Table 1 Patient characteristics, comorbidities and parameters of quality of life
| N=163 | |||
|---|---|---|---|
| Groups | Non-vasodilating Beta-blockers (n= 132) | Vasodilating Beta-blockers (n=31) | P value |
| Gender n,(%)} | Male : 99 (75.3%) | 18 (58.7%) | 0.051 |
| Age (yrs) | 66.7±12.2 | 67.0±13.2 | ns |
| Left ventricle EF (%) | 39.9±12.2 | 39.7±11.3 | ns |
| LVIDd(cm) | 6.4±1.0 | 6.2±1.1 | ns |
| Haemoglobin (g/dL) | 13.1±1.6 | 13.0±1.5 | ns |
| eGFR (ml/min | 58.6±18.0 | 54.7±19.2 | ns |
| Anti-proBnp | 1243±1812 | 1692±2253 | ns |
| Heart rate | 71.0±14.7 | 69.8±15.27 | ns |
| Comorbidities | n (%) | n (%) | |
| Ischaemic cardiomyopathy | 58 (43.4) | 12 (38.7) | ns |
| Diabetes | 25 (18.6) | 5 (16.1) | ns |
| Renal disease | 55 (41.7) | 17 (51.9) | ns |
| Hypertension | 75(56.8) | 17(56.8) | ns |
| COPD | 16(12.1) | 6 (19.4) | ns |
| Smokers | 7 (9.2) | 11(12.6) | ns |
| Ex-smoker | 46 (60.5) | 43(49.4) | ns |
| Treatment | |||
| ACE inhibitors | 122(92.4) | 31(100) | ns |
| Calcium blockers | 17 (12.9) | 2 ( 6.5) | ns |
| MR antagonists | 91 (68.9) | 24 (77.3) | ns |
| Devices | 12 (9.1) | 3 ( 9.7) | ns |
| KCCQ -7 score | |||
| Physical limitation | 69.7±22.2 | 67.6±32.1 | ns |
| Symptom stability | 54.3±17.4 | 54.8±18.6 | ns |
| Symptom frequency | 75.5±17.4 | 74.6±24.6 | ns |
| Symptom Burden | 77.5±23.2 | 77.1±25.4 | ns |
| Symptom Total score | 76.9±23.2 | 74.6±26.5 | ns |
| Self-efficacy | 78.2±23.8 | 75.9±30.0 | ns |
| Quality of life | 66.8±27.0 | 64.7±26.7 | ns |
| Social limitation | 66.7±29.6 | 66.6± 29.7 | ns |
| Overall summary | 70.222.6 | 68.425.7 | ns |
| Clinical summary | 73.4±23.1 | 72.2±22.6 | ns |